FDA Head Calls for Probe Into Alzheimer’s Drug Review

FDA Head Calls for Probe Into Alzheimer’s Drug Review
A vial and packaging for the drug Aduhelm is shown on June 7, 2021. Biogen via AP
The Associated Press
Updated:

WASHINGTON—The acting head of the Food and Drug Administration on Friday called for a government investigation into highly unusual contacts between her agency’s drug reviewers and the maker of a controversial new Alzheimer’s drug.

Dr. Janet Woodcock announced the extraordinary step via Twitter. It’s the latest fallout over last month’s approval of Aduhelm, an expensive and unproven therapy that the agency OK'd against the advice of its own outside experts.